Last update 07 Sep 2023

Centhaquine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
PMZ-2010, Lyfaquin
Target
ADRA2B + α2A-AR(Alpha-2b adrenergic receptor + Alpha-2a adrenergic receptor)
Mechanism
ADRA2B agonists(Alpha-2b adrenergic receptor agonists), α2A-AR agonists(Alpha-2a adrenergic receptor agonists)
Therapeutic Areas
Other Diseases, Infectious Diseases, Respiratory Diseases
Active Indication
Shock, Hemorrhagic, Shock, COVID-19
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Highest Phase (Global)Approved
First Approval Date(Global)
IN (May 2020),
Shock, Hemorrhagic
Regulation-
Login to view First Approval Timeline

R&D Status

IndicationHighest PhaseCountry/LocationOrganization
Shock, HemorrhagicApprovedIN
More
ShockPhase 3 ClinicalIN
More
COVID-19Phase 2 Clinical-
Login to view more data

Clinical Trial Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Shock
Adjuvant
197
zohkepkyrb: odds ratio = 4.4 (95% CI, 0.9651 ~ 23.74)
Positive
05 Nov 2020
Login to view more data

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial Analysis

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.